{
    "nctId": "NCT05945927",
    "briefTitle": "A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer",
    "officialTitle": "An Observational Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Second- or Later-Line Therapy in Chinese Patients With HER2 Positive Advanced Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 500,
    "primaryOutcomeMeasure": "Percentage of Participants with Adverse Events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with HER2-positive, unresectable locally advanced or metastatic breast cancer before the start of T-DM1 treatment\n* Had prior treatment for breast cancer which must contain a taxane and trastuzumab\n* Get the treatment of T-DM1 for the first time after diagnosis of breast cancer\n\nExclusion Criteria:\n\n* Patients not receiving treatment for HER2-positive breast cancer with T-DM1 according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling\n* Has been previously treated with T-DM1 before current clinical visit\n* Currently participating in any clinical trials\n* Previously participated in any clinical trials investigating anti-HER2 drug within 1 year of the initiation of T-DM1",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}